

May 19, 2014



Actinium to Present at the Third Annual Marcum Microcap Conference in NYC on May 29th

CEO To Provide Corporate Update on Late-Stage Iomab™-B Trial and Ongoing Actimab-A Phase 1/2 Trial

NEW YORK-- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

The Company's presentation is scheduled to begin at 9:30 a.m. EDT and will be available via a live webcast. To access the live audio webcast of the Marcum presentation, please log on through a link located in the Investors section of Actinium's website at www.actiniumpharma.com under the Corporate Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.

Dr. Dave and other members of the management team will be available for one-on-one meetings at the conference. Members of the investment community who are interested in meeting with management should contact their Marcum representative, or Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or esmith@actiniumpharma.com.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than \$500 million in market capitalization.

For more information or to register, please visit the conference website at <http://www.marcumllp.com/microcap> or download the free official conference app for the iPhone, iPad, or for Android mobile devices in Apple's App Store and the Google Play Market.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharmaceuticals.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab™-B will be used in preparing

patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; Marcum Buchanan Associates LLC; and Marcum Cronus Partners LLC. For more information, visit www.marcumllp.com.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For Actinium Pharmaceuticals, Inc.
Evan Smith, CFA, 646-840-5442
VP Investor Relations and Finance
Email: esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals, Inc.